NCT04948333 2026-03-18
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
Phase 3 Completed
Novartis
Gustave Roussy, Cancer Campus, Grand Paris
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Merck Sharp & Dohme LLC
Shenzhen TargetRx Co., Ltd.
Fudan University
Takeda